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blood pressure monitoring (ABPM) is
more expensive than traditional blood
pressure measurement. However,
ABPM can identify some patients with
normal average blood pressures despite
apparent hypertension on office read-
ings (ie, “white coat” hypertension).
Such patients do not require treatment.
ABPM has been used extensively in
specialist hypertension clinics. The
reported prevalence of white coat hyper-
tension among newly diagnosed people
with hypertension is about 20%,1 but
this is greatly influenced by the cut
points used.2 The rate of progression to
sustained hypertension is estimated to
be 10% per year.3
We set out to compare the savings
made through not treating white coat
hypertension with the costs of ABPM of





Previously untreated patients diagnosed
as having hypertension by conventional
blood pressure measurement were
recruited from general practitioners in
two Divisions of General Practice from
August 1996 to February 2000. The
entry criterion was that the GP had
decided the patient needed antihyper-
tensive drug treatment. GPs were
prompted that there should have been
three readings showing diastolic blood
pressure  95 mmHg; however, this
was not a requirement, so this study
reflects usual practice. We did not insist
on “gold standard” clinical measure-
ment of blood pressure, as this may not
be usual care in general practice.
Blood pressure monitoring
Monitoring with a QuietTrak (Welch
Allyn, Skaneateles Falls, NY) auscul-
tory automatic sphygmomanometer was
performed for a single 24-hour period
using an appropriate-sized cuff, after
calibration against a mercury sphygmo-
manometer on each subject. During set-
up, each patient was asked his or her
usual time of going to bed and rising,
and the monitor was set to record blood
pressure each half-hour during the day
and evening and hourly while they were
in bed. Rise and sleep times were all
within an hour of 6:00 AM and 10:00
PM, as used in the Verdecchia criteria.
We used Verdecchia’s 19944 threshold
values of a daytime (6:00 AM to 10:00
PM) average of  131/86 mmHg in
women and  136/87 mmHg in men.
The QuietTrak has been previously
shown to meet the standards set down
in the Association for the Advancement
of Medical Instrumentation guideline in
validation studies.5 The result was fed
back to the referring GP for treatment
decisions, with interpretation advice fol-
lowing Verdecchia’s threshold values.
The study was approved by the Alice
Springs Institutional Ethics Commit-
tee, and the ethics committee of the
Royal Australian College of General
Practitioners.
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ABSTRACT
Objective:  To compare the cost of ambulatory blood pressure monitoring (ABPM) 
with the putative savings made through treatment avoided by identification and non-
treatment of those with “white coat” hypertension.
Design:  A cost analysis based on a model of four alternative strategies (no ABPM, 
yearly, two-yearly, or three-yearly monitoring) over a seven-year period applied to a 
case series from Australian general practice.
Participants:  62 patients newly diagnosed by their GPs as having hypertension 
and requiring drug treatment.
Main outcome measures:  The proportion of patients shown to not need 
treatment. The discounted costs to the Pharmaceutical Benefits Scheme, Medical 
Benefits Scheme and patients.
Results:  16 of 62 patients (26%; 95% CI, 15%–37%) were normotensive on ABPM 
and did not require treatment. All monitoring strategies are more expensive in the 
first year, but the initial costs are offset by year 3 and the monitoring strategies are 
cost saving thereafter. Sensitivity analysis shows that this result holds across a 
range of costs of pharmacotherapy and proportion of patients with white coat 
hypertension.
Conclusion:  The additional costs of 24-hour ABPM in the first year are offset by 
savings associated with patients with white coat hypertension who would otherwise 
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Cost analysis
The cost analysis compared four alter-
native strategies, as described in Box 1.
The costs considered were cost of
pharmaceuticals, consultations, pathol-
ogy and ABPM. The perspectives of the
Pharmaceutical Benefits Scheme
(PBS), Medical Benefits Scheme
(MBS) and patients were considered.
The objectives of the cost analysis were
to:
■ provide an estimate of the discounted
annual financial costs of each strategy;
■ estimate the number of years before
which the additional costs in year one
would be offset by the savings from
reduced treatment costs in subsequent
years; and
■ inform discussion of the merits of
listing such an item on the MBS.
Model structure
A model was constructed to simulate
the costs over a seven-year period of
treating a cohort of 100 patients diag-
nosed with hypertension under the four
strategies.
Key assumptions of the model
include:
■ patients are monitored at the start of
the year;
■ patients with white coat hypertension
not receiving treatment and who
become hypertensive over the year will
become hypertensive at the end of that
year; and
■ patients will have one standard GP
consultation before each episode of
monitoring.
The inclusion of a second monitoring
at year one in all three monitoring strat-
egies addresses clinicians’ anxiety about
withholding treatment on the basis of
just one test result. A seven-year period
was chosen so that three and two cycles
of strategies 3 and 4, respectively, were
completed.
In addition to the cost analysis, esti-
mates were made of the number of years
of treated white coat hypertension and
untreated real hypertension for each of
the strategies.
A sensitivity analysis was performed
to test the robustness of the results to
key assumptions.
A threshold analysis, which tested the
sensitivity of thresholds for decision-
making purposes, was also performed.
Costs
The costs of providing ABPM are
dependent on the capital costs of the
equipment, staff time for set-up,
detachment and data handling, volume
of tests done, life span of the equip-
ment, depreciation rates, and institu-
tional overheads. As the test is not
generally commercially available, it was
necessary to estimate the likely com-
mercial cost per test if it were widely
introduced. An estimate of the cost per
patient of providing the service was
made using cost data collected during
the trial. Using three-year depreciation,
the expected cost varies between $140
and $133 per patient for annual
throughputs of 100 and 150 patients,
respectively.
Currently, there is no item for ABPM
on the MBS schedule, so the likely cost
to the MBS if it were listed was esti-
mated using the Medical Services Advi-
sory Committee guidelines.6 The
guidelines consider both the full costs of
a procedure and reference to similar
items already on the MBS schedule.
Two items for 24-hour ECG monitoring
(MBS Items 1109 and 1108) are similar
procedures that are generally available
commercially, with scheduled fees of
$130.40 and $99.55, respectively. A
proposed fee of $128.80 is consistent
with the costs of provision and with the
current schedule. The cost to the MBS
of the ABPM used for our model was
$133, being 85% of the proposed
scheduled fee plus the rebate for a level
B general practitioner consultation.
This estimate was varied in the sensitiv-
ity analysis.
Pharmaceutical costs for the treat-
ment of hypertension are based on the
study by Nelson et al,7 which presented
an estimate of 1 223 000 Australians
receiving an average of 1.6 antihyper-
tensive medications each under the PBS
in 1998, at a cost of $365.3m per year to
the government and a further $110.9m
to consumers through copayments. Per
patient, this equates to $299 to the PBS,
$90 in patient costs, and $389 in total
drug-acquisition costs. There is a bias
inherent in these estimates of cost to
consumers, as the PBS data do not
include drugs costing patients less than
the copayment amount of $21.90 per
script. The effect of this bias is to
underestimate the savings to patients of
strategies that reduce the number of
patients treated. For comparison, the
total annual drug-acquisition cost per
patient at standard doses for atenolol is
$117, ramipril $459, and felodipine
plus ramipril $827.
There are no Australian data on the
costs of consultations and pathology
tests in the care of hypertensive patients,
so we have used the conservative
assumptions of two level B general prac-
tice consultations at a cost to the MBS
of $23.50 each, and one pathology test
at a cost of $20 per year. Most patients
will be seen more frequently during the
first months of treatment, but, without
observational data, we have allowed
only two consultations a year. The max-
imum prescribed quantity for most
drugs is a six-month supply, so two
consultations per year is the minimum
possible. The cost to the patient
depends upon fee structures and
whether they are concessionary or non-
concessionary patients. We have
excluded consideration of this cost.
Model inputs
Box 2 summarises the inputs used in the
base case of the model and the sensitiv-
ity analysis. Sources of estimates are
discussed above.
From a government perspective, a key
decision threshold is whether ABPM is
likely to remain cost saving for a full
range of possible values of key variables.
We assumed a threshold for financial
1: Strategies evaluated in the model
Strategy 1: No ABPM Drug treatment, no monitoring
Strategy 2: Annual ABPM Monitor initially, withhold treatment if WCH demonstrated, 
and re-monitor annually if not on treatment.
Strategy 3: Two-yearly ABPM Monitor initially, withhold treatment if WCH demonstrated, 
and re-monitor at years 1, 3 and 5 if not on treatment.
Strategy 4: Three-yearly ABPM Monitor initially, withhold treatment if WCH demonstrated, 
and re-monitor if not on treatment at years 1 and 4.
ABPM = ambulatory blood pressure monitoring. WCH = white coat hypertension.
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viability of ABPM that requires the
additional costs in the first year to be
offset by savings in the following two
years (ie, the strategy becomes cost
neutral compared with usual care by the
end of three years). We believe this is a
conservative threshold. We then used
the base-case values of all variables and
varied first the prevalence of white coat
hypertension and then treatment costs
until strategy 2 was cost neutral by the
end of year 3.
RESULTS
1.Results
The 62 patients (44 women) had a
median blood pressure of 154/
98 mmHg, as recorded by the referring
GP. The prevalence of white coat hyper-
tension in our group of newly diagnosed
hypertensive patients was 16/62 (26%;
95% CI, 15%–37%). This is similar to
the results of other series.8 Adverse
outcomes of monitoring were sleep dis-
turbance for two patients.
The results of the model over a seven-
year period (Box 3) indicate that all the
strategies including monitoring are cost
saving when compared with no moni-
toring. All monitoring strategies are
more expensive than strategy 1 in the
first year, but break even after the third
year (ie, the additional costs in the first
year are offset by savings in the subse-
quent two years). The average govern-
ment cost per patient over seven years is
$317 for a strategy that does not include
ABPM, which is more than for the other
strategies (Box 3).
Comparison of the performance of
each strategy revealed that the incre-
mental costs for a group of 100 patients
over seven years of moving from strategy
4 to strategy 2 is $13 700, preventing 12
years of untreated true hypertension at a
cost of $1141 per patient-year. Under
each of the monitoring strategies,
patients with white coat hypertension
would not be treated, representing 19%
of total patient-years.
Sensitivity analysis
A univariate sensitivity analysis was per-
formed for each of four variables, within
the ranges indicated in Box 2. Even
though financial indicators of cost per
patient per year over seven years and
savings per patient are sensitive to
assumptions regarding the key varia-
bles, all the monitoring strategies
remain less expensive than no monitor-
ing (Box 4).
Threshold analysis
The threshold analysis indicated that,
with all other variables at the base case,
the threshold prevalence of white coat
hypertension is 17%, below which strat-
egy 2 is no longer cost saving at three
years. Similarly, with all other variables
at base case, if treatment costs were
below $332 strategy 2 would no longer
be cost saving at three years. Finally,
with a prevalence of white coat hyper-
tension of 20% and a cost of treatment
per year of $400, the strategy is cost
neutral at the end of year 3.
This analysis suggests that it is likely
that strategy 2 will be cost neutral
within three years, and result in finan-
cial savings thereafter, even if the preva-
lence of white coat hypertension and the
treatment costs, the main determinants




Our study provides evidence that the
introduction of ABPM to the routine
diagnosis of hypertension in Australian
general practice would be cost saving if
it were used in a manner similar to our
study to confirm sustained hypertension
before initiating drug treatment.
There is evidence to support the clin-
ical practice of not treating white coat
hypertension. There have been six
cohort studies4,9-13 of cardiovascular
outcomes after 24-hour ABPM, in
which large groups of subjects have
been followed for up to 13 years.
2: Model Inputs
Variable Base case estimate Low value High value
Total annual costs of blood pressure 
for treated patients
$456 $396 $506




Annual costs to patients of pharmacotherapy $90
Annual costs to MBS of consultations 
and pathology
$67 
Total annual costs for untreated patients
Cost of monitoring if 
occurred in that year
Cost of monitoring including consultation 
$23.50 (proposed government share) 
$133 — $160
Cost of monitoring excluding consultation 
(proposed patient share)
$20 — $24
Discount rate 0.05 — —
Proportion with WCH 26% 15% 37%
Proportion of WCH progressing to true 
hypertension per year
0.1 0.05 0.15
MBS = Medical Benefits Scheme. PBS = Pharmaceutical Benefits Scheme. WCH = white coat hypertension.
3: Results of cost analysis
Cost per patient 
in year one 
Cost per patient 
in year three
Average cost per  
patient over 
seven years
Savings per year per patient 
compared with strategy 1 
(% of strategy 1 cost)
Govt Total Govt Total Govt Total Govt Total
Strategy 1* $366 $456 $332 $413 $317 $396 — —
Strategy 2 $404 $490 $290 $359 $294 $362 $23 (7%) $34 (8%)
Strategy 3 $404 $490 $254 $317 $282 $350 $35 (11%) $46 (12%)
Strategy 4 $404 $490 $254 $317 $277 $343 $40 (13%) $53 (13%)
* See Box 1 for descriptions of strategies. Govt = costs to the government (Pharmaceutical Benefits Scheme 
and Medical Benefits Scheme). 
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Although these studies differed widely
in design, all suggest that ambulatory
blood pressure gives a better prediction
of prognosis than clinic blood pressure.
The corollary is that patients with white
coat hypertension have a more benign
prognosis than those with sustained
hypertension, and treatment thresholds
could be better determined by ABPM.
Some authors14,15 are more guarded
about the significance of white coat
hypertension, and there is evidence that
white coat hypertension can eventually
progress to sustained hypertension.
Our sensitivity and threshold analyses
demonstrate that monitoring, although
more expensive in the first year,
becomes cost neutral after three years
and cost saving thereafter. This holds
true over a reasonable range of values of
key variables. A strength of this study is
that GPs were asked to decide on con-
ventional grounds that drug treatment
was indicated before ordering ambula-
tory monitoring. These patients were all
about to commence drug treatment, so
the result reflects the realities of current
Australian practice.
A limitation of the current study is its
small sample size; however, larger
series6 have shown a similar prevalence
of white coat hypertension. Although
use of observed costs from the partici-
pating practices would have been
sounder economic practice, national
cost estimates for the treatment of
hypertension are a reasonable substi-
tute. The use of break-even threshold
analysis allows application of the model-
ling results to patient series from other
settings. The strategies compared took
as their starting point the decision by
the GP that drug treatment was neces-
sary. In widespread use, ABPM is likely
to be ordered earlier in the workup of
hypertensive patients, resulting in the
saving of some consultation costs and
the ABPM monitoring of a greater
number of patients. These effects can-
not be assessed by this study.
Monitoring was well tolerated in this
study, and readily adopted by GPs and
patients. Patients shown to have low 24-
hour average blood pressures were often
greatly relieved not to start lifelong
medication, and those with sustained
hypertension were anecdotally more
accepting of the diagnosis after ABPM,
which may aid compliance.
Risks of ABPM are, firstly, of false
results if adequate quality assurance
protocols are not adhered to. Monitors
must be calibrated to a reference sphyg-
momanometer during the set-up for
each patient, which can be time con-
suming. Secondly, the results must be
interpreted against ABPM reference
values, not against clinic blood pressure
values. Clinicians could mistakenly
deny treatment to patients who would
benefit if they compared 24-hour results
with the conventional treatment thresh-
old, such as diastolic pressures of
95 mmHg.
An alternative strategy to detect white
coat hypertension is home monitoring
with semi-automated devices. This
involves cheaper equipment, but more
time teaching the patient the method.
Home monitoring strategies should be
subjected to similar analysis.
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4: Key results of sensitivity analysis
Total annual costs per patient: average over seven years
(savings per patient per year compared with strategy 1)
Cost of treated  
hypertension: 
reduce by 
20% to $396 









Rate of progression 
from WCH to true 
hypertension per year: 
increase from 
10% to 15%
Strategy 1* $344 $396 $396 $396
Strategy 2 $320 ($24) $371 ($25) $385 ($11) $369 ($27)
Strategy 3 $308 ($36) $356 ($40) $378 ($18) $357 ($39)
Strategy 4 $302 ($42) $349 ($47) $374 ($22) $350 ($46)
See Box 1 for description of strategies. WCH = white coat hypertension.
